Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 3/20 | 0.30 |
| ▸ | HTR2C | P28335 | 3/20 | 0.30 |
| ▸ | HTR2B | P41595 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31618296 | 0.82 | TDP2 (0.37) | TDP2PARP1PARP10GPR3PNMT | |
| SCHEMBL31064284 | 0.82 | TDP2 (0.43) | TDP2PARP1PARP10GPR3HTR2A | |
| SCHEMBL31064426 | 0.76 | METAP1 (0.40) | TDP2 | |
| SCHEMBL31064506 | 0.76 | — | — | |
| SCHEMBL31064412 | 0.73 | PDK2 (0.38) | — | |
| SCHEMBL30574140 | 0.72 | SLC6A3 (0.37) | TDP2PDE2A | |
| SCHEMBL30574162 | 0.72 | TDP2 (0.36) | TDP2PARP1PARP10PNMTHTR2A | |
| SCHEMBL3745692 | 0.70 | HTR2C (0.38) | TDP2PARP1PARP10HTR2AHTR2C | |
| SCHEMBL30574127 | 0.69 | TDP2 (0.39) | TDP2PARP1PARP10 | |
| SCHEMBL31544263 | 0.68 | TDP2 (0.41) | TDP2PARP1PARP10GPR3PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688785-A1 | 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | Beone Medicines I GmbH (CH) | 2026-02-11 | — | — | EP | disclosed |
| US-20240368177-A1 | 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE SWITZERLAND GMBH (CH) | 2024-11-07 | — | — | US | disclosed |
| WO-2024199255-A1 | 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-d] PYRROLO [3, 2-b] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE SWITZERLAND GMBH (CH) | 2024-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368177-A1 | 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | PRMT5, PRMT6, PRMT1 | TDP2 412/4885PARP1 322/4885PARP10 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.